Objective. Determine outcomes of cooled radiofrequency ablation (C-RFA) of the genicular nerves for treatment of chronic knee pain due to osteoarthritis (OA).
Introduction
Chronic pain from knee osteoarthritis (OA) is a common problem [1] [2] [3] that frequently leads to total knee arthroplasty (TKA), yet this surgery is associated with a variety of perioperative and postoperative risks, including chronic pain in nearly 20% of patients following TKA [4, 5] . Many patients with knee OA elect to avoid surgery, and others are poor candidates due to medical comorbidities [6] .
Recently, genicular nerve radiofrequency ablation (RFA) was introduced as a treatment option for patients who have failed to respond to conservative pain management of knee osteoarthritis who are poor surgical candidates or wish to avoid TKA [7] [8] [9] [10] [11] . As with other ablation techniques where sensory afferent pathways are disrupted, this technique involves thermal lesioning of the superior lateral, superior medial, and inferior medial genicular nerves, sometimes called the retinacular nerves [7, [9] [10] [11] . Together, these nerves are responsible for afferent pain signaling of the anterior joint capsule [12] . While outcome literature regarding joint denervation by radiofrequency ablation exists for zygaphophysial and sacroiliac joint pain [13] [14] [15] [16] [17] [18] [19] , few outcome studies of genicular nerve RFA have been published [7, 8, 11] . The purpose of this study was to determine six-month clinical outcomes of genicular nerve cooled radiofrequency ablation (C-RFA) for the treatment of chronic pain due to primary knee osteoarthritis, as measured by change in pain, global subjective improvement, analgesic medication use, and avoidance of TKA. This study also aimed to identify factors that predict a clinically significant treatment response.
Methods

Study Population
This was a cross-sectional survey study and retrospective chart review conducted at an urban academic pain medicine center. Institutional review board approval was obtained (STU00201290). Consecutive patients, treated between October 2014 and September 2015, identified by electronic medical record query of C-RFA current procedural terminology (CPT) codes, were included in the study if the following criteria were met: 1) age 18 to 89 years; 2) native symptomatic knee(s); 3) 50% or greater concordant pain relief of typical knee pain during walking and weight bearing following a set of diagnostic superiomedial, superiolateral, and inferomedial genicular nerve blocks with 1 mL of 2% lidocaine at each location; 4) C-RFA of the superiomedial, superiolateral, and inferomedial genicular nerves; 5) at least a six-month time period since the genicular C-RFA procedure was performed.
Figure 1
Anterior/posterior (A-P) (A) and lateral (B) fluoroscopic images of the final needle positions during diagnostic block genicular nerve blocks are shown. The superior lateral site is identified at the confluence of the lateral femoral shaft and the lateral femoral condyle in the A-P plane and the midpoint of the femur in the lateral plane. The superior medial site is identified at the confluence of the medial femoral shaft and the medial femoral condyle in the A-P plane and the midpoint of the femur in the lateral plane. The inferior medial site is identified at the confluence of the medial tibial shaft and the tibial flare in the A-P plane and the midpoint of the tibia in the lateral plane. Of note, the lateral view (B) shows some obliquity in which the femoral condyles are not perfectly superimposed. This is ideally avoided. The lateral view during electrode placement (shown in Figure 2B ) represents a more ideal view with no obliquity.
Diagnostic Genicular Nerve Block Procedure
The patient was positioned supine on a fluoroscopy table with a bolster to provide 30 to 40 of flexion in the treated knee joint. The foot and ankle were secured to the fluoroscopy table with wide, durable tape to stabilize the leg during the procedure. Using a 25-gauge needle, a skin wheal of 1 to 2 mL of 1% lidocaine was used for superficial local anesthesia in order to avoid spread to the genicular nerves (a potential cause of false positive block results). A 25-gauge 2.5 to 3.5 inch Whitacre needle was placed at three unique anatomic sites to block the following neural structures: the superior lateral, the superior medial, and the inferior medial genicular nerves. The superior lateral genicular nerve is located at the confluence of the lateral femoral shaft and the lateral femoral condyle (in the anteroposterior [A-P] plane) and at the midpoint of the femur (in the lateral plane). The superior medial genicular nerve site is located at the confluence of the medial femoral shaft and the medial femoral condyle (in the A-P plane) and at the midpoint of the femur (in the lateral plane). The inferior medial genicular nerve site was located at the confluence of the medial tibial shaft and the tibial flare (in the A-P plane) and the midpoint of the tibia (in the lateral plane) [12] . Accurate and precise needle placement was confirmed using fluoroscopy in both the A-P and lateral planes, taking extra care to ensure that the condyles of the femur were superimposed over one another during lateral imaging to eliminate obliquity. Needle placement sites are shown in Figure 1 . At each needle site, 1.0 mL of 2% lidocaine was injected in order to anesthetize each genicular nerve.
Genicular Nerve Radiofrequency Ablation Procedure
Patient positioning and monitoring was identical to the diagnostic genicular nerve block procedure. Conscious sedation (midazolam 1-2 mg IV and/or fentanyl 25-100 mcg IV) and supplemental nasal cannula oxygen were administered. Skin and soft tissues were anesthetized with 1 to 2 mL of 1% lidocaine at each of the three anatomic sites for RFA, and a 50 or 75 mm 17-gauge introducer needle was placed to lesion the superior lateral, superior medial, and inferior medial genicular nerves. Once the introducer needle was placed, the 18 g internally cooled, 4 mm active tip. RFA electrode (Coolief, Halyard Health, Alpharetta, GA, USA) was placed into the introducer needle, and positioning was verified with A-P and lateral fluoroscopic views. After motor nerve activity was ruled out with testing at 2 Hertz at 1 mA, 1 mL of 2% lidocaine was injected through the introducer needles to anesthetize the region prior to thermal ablation. Each target was sequentially lesioned for two minutes and 30 seconds at a set temperature of 60 C, which imparts a tissue temperature of 77 to 80 C surrounding the electrode [20] . Electrode position is shown in Figure 2 .
Data Collection
The electronic medical record was reviewed for each patient in order to collect data regarding demographic, clinical, and procedural characteristics including age, sex, body mass index (BMI), duration of pain at presentation, smoking status, alcohol consumption, history of meniscectomy, marital status, percent pain relief from the diagnostic genicular nerve blocks, and laterality of the C-RFA procedure. At least six months following the C-RFA procedure, all participants were administered a standardized survey by telephone that included their current numeric rating scale (NRS) for knee pain, the Medication Quantification Scale III (MQS III) [21] , Patient Global Impression of Change (PGIC), and query of knee pain treatments since the C-RFA procedure (Appendix A).
Outcome Measures
The primary outcome, treatment success, was defined as a combination of 50% or greater reduction in NRS score and PGIC score consistent with "very much improved" or "improved," and no TKA. A secondary definition of treatment success was also defined based on improvement in NRS score equal to the minimal clinically important change for chronic pain: a two-point reduction [22, 23] . MSQ III data were analyzed according to a change of 3.4 or more points, the equivalent of approximately five oral morphine equivalents or ibuprofen 600 mg three times daily. Categorical data were used given that studies on interventional pain procedures may result in responders and nonresponders, thus negating the ability to use mean or average data [24, 25] . Additionally, this approach for assessing spine pain has been recommended by the National Institutes of Health [26] . Intention-to-treat analysis was used to account for patients lost to follow-up in the categorical analysis. Demographic, clinical, and procedural characteristics were compared in participants who met the definition of clinical success in order to determine factors associated with a positive outcome.
Statistical Analysis
The Shapiro-Wilk and Kolmogorov-Smirnov tests were used to test the hypothesis of normal distribution. Nonnormally distributed interval and ordinal data are reported as median (interquartile range) and compared between clinical success and nonclinical success groups using the Mann Whitney U test. Binomial confidence intervals were calculated using the ClopperPearson method. Binomial proportions between clinical success and nonclinical success group data were compared using Fisher's exact test. A backward stepwise (likelihood ratio) binary logistic regression model for clinical success was constructed using the variables BMI, duration of pain at presentation, percentage pain relief from diagnostic blocks, and procedure (unilateral or bilateral). Odds ratios and 95% confidence intervals for the odds ratios were calculated for variables in the final model. Model performance and 95% confidence interval were assessed with the area under the receiver operating characteristics (ROC) curve. A P value of less than 0.05 was required to reject the null hypothesis. Data analysis was performed using SPSS version 23 
Results
Thirty-three patients (52 C-RFA procedures on discrete knees) met inclusion criteria. Three patients (three knees) were lost to follow-up and were thus considered treatment failures. Five patients (seven knees) underwent TKA and were thus considered treatment failures. Baseline demographic, clinical, and procedural characteristics are shown in Table 1 . A median duration of eight (interquartile range [IQR] ¼ 6-10) months elapsed after C-RFA to the time of outcome survey. There were no reported serious adverse events related to the C-RFA procedure.
Clinical outcomes at a minimum follow-up of six months for the entire group are shown in Tables 2 and 3 . The median reduction in pain was 2 (IQR ¼ 0-6) on the NRS scale. Thirty-seven percent (95% confidence interval [CI] ¼ 24%-50%) and 50% (95% CI ¼ 36%-64%) of procedures resulted in 50% or greater and a reduction of two or more points in NRS score, respectively. Nineteen percent (95% CI ¼ 10%-33%) of procedures resulted in complete relief of pain. The median reduction in MQS III score was 3 (IQR ¼ 0-6), and the proportion of patients with a reduction of 3.4 or more was 40% (95% CI ¼ 27%-54%). A PGIC score consistent with "very much improved" or "improved" was after 35% (95% CI ¼ 22%-48%) of procedures. Thirty-five percent (95% CI ¼ 22%-48%) of procedures met the stringent definition of treatment success based on the criteria of 50% or greater reduction in NRS score and PGIC score consistent with "very much improved" or "improved," and no TKA.
Demographic, clinical, and procedural characteristics stratified by patients who met the definition of clinical success vs those who did not meet this definition are shown in Table 4 . Duration of pain of less than two years at the time of presentation was the only factor associated with clinical success on univariate analysis. Multivariable predictors of clinical success are shown in Table 5 . BMI, duration of pain at presentation, and percentage relief from diagnostics block were included in the model. The area under the receiver operator characteristic curve was 0.88 (95% CI ¼ 0.78-0.97, P < 0.001). Binary performance at a predicted probability cutoff value of 0.5 are sensitivity 67% (95% CI ¼ 41%-87%), specificity 88% (95% CI ¼ 72%-97%), positive predictive value 75% (95% CI ¼ 48%-93%), and negative predictive value 83% (95% CI ¼ 67%-94%).
Discussion
This study investigated clinical outcomes of patients who underwent genicular nerve C-RFA for the treatment of chronic knee pain due to primary osteoarthritis, adding evidence of positive outcomes associated with this technique in a proportion of patients even when relatively lenient diagnostic block selection criteria (!50% relief) are used. When the criterion for success is defined as the minimal clinically important change for chronic pain, similar to other studies of RFA technology [27, 28] , the success rate is 50% (95% CI ¼ 36%-64%). Forty percent (95% CI ¼ 27%-54%) of patients reduced analgesic medication use by 3.4 or more points by MQS III score, the equivalent of approximately 5 oral morphine equivalents or ibuprofen 600 mg three times daily. When a stringent definition of success based on a combination of robust patient-reported outcome measures and lack of escalation to TKA is used, the data indicate a success rate of 35% (95% CI ¼ 22%-48%). Interestingly, when the criteria for treatment success is defined by complete relief of pain in addition to the a positive PGIC score and lack of TKA, the rate of success falls to 19%, but the lower bound of the 95% confidence interval does not cross zero (95% CI ¼ 10%-33%). It is notable that a nonzero proportion of patients experienced complete pain relief at a minimum of six months of follow-up given that patients in this cohort had knee pain that failed to respond to comprehensive conservative care including injection therapy, which typically results in TKA. This finding is reinforced by the fact that only 13% of patients underwent TKA during the follow-up period; only 15% of patients in this cohort were considered to be poor surgical candidates due to medical comorbidities. Longer-term follow-up studies will be needed to determine if genicular nerve C-RFA can prevent TKA beyond six months.
The results of an exploratory multivariate logistic regression analysis demonstrate that duration of pain at presentation and percentage relief from diagnostics block are predictive of the likelihood of treatment success. However, given the size and retrospective design of this study, these factors need confirmation in a larger prospective study of genicular nerve ablation. It is also likely that additional unidentified factors exist. Within the context of guarded interpretation, the present data do suggest that the diagnostic block paradigm may need to be refined as the false positive rate in this study was high, consistent with studies that have demonstrated high false positive rates associated with diagnostic nerve blocks for facet joint anesthesia [29, 30] . There is presently no literature that defines an appropriate threshold of pain reduction and the appropriate number of diagnostic blocks needed to optimize patient selection for the genicular nerve C-RFA procedure. Such evidence-based algorithms have been developed for zygapophyseal and posterior sacroiliac joint/dorsal ligament complex denervation [31] [32] [33] , and parallel work is needed for genicular nerve C-RFA.
There may be alternative reasons for the high rate of "false positive" diagnostic blocks observed. Because sensory nerve stimulation was not used, but rather anatomic placement of the electrodes based on cadaveric study by Franco et al. [12] , the genicular nerves may have been incompletely denervated when using this technique. Sensory nerve stimulation was not performed as a prior study of facet joint denervation by RFA has demonstrated no correlation between sensory stimulation thresholds and clinical outcomes [34] . However, such a study is needed specifically for genicular nerve denervation as these findings may not apply outside of lumbar facet joint procedures.
There is a paucity of high-quality literature with which to compare the present findings. In the only randomized prospective study of genicular nerve conventional (not cooled) RFA for knee pain for primary osteoarthritis [7] , Choi et al. allocated 38 participants to undergo unilateral genicular RFA with conventional thermal lesioning or to a sham control group that underwent local anesthetic injections with a three-month follow-up duration. The authors found that 59% of those in the treatment group experienced 50% or greater reduction in pain scores at the end of the follow-up period, whereas the control group experienced essentially no difference in pain levels at the same time point. In an open label, nonrandomized [8] , controlled study, Ikeuchi et al. compared genicular nerve conventional (not cooled) RFA to genicular nerve block (N ¼ 35) for pain related to isolated anteromedial knee pain related to OA and followed participants up to six months. These investigators found the proportion of responders (!50% reduction in pain score) to be 50%, 30%, and 10% at one, three, and six months, respectively. Shen et al. report an additional prospective, nonrandomized comparative study of genicular nerve conventional (not cooled) RFA vs "regular treatments," but do not report treatment response rates [11] .
The present study showed a success rate lower than While there is insufficient data to suggest that higher BMI predicts poorer outcomes after genicular radiofrequency ablation, this is plausible. The present study included patients who had prior knee arthroscopy, where Choi et al. excluded these patients. Further, more than half of the patients in the present study underwent bilateral procedures due to bilateral pain and OA, which may suggest a more disabled study population and a lower ceiling for possible improvement. In fact, exploratory subanalysis indicated that unilateral genicular RFA may be associated with superior clinical outcomes. Finally, outcomes were measured at least six months after the C-RFA procedure, and, in fact, the median duration between the procedure and outcome assessment was eight months. Studies of C-RFA for other pain syndromes show diminished pain relief six months after ablation [18, 19] . This is specifically supported following genicular nerve ablation by the Ikeuchi et al. study as the success rate degraded from 50% to 10% at onemonth compared with six-month follow-up. We did not query patients with regard to pain relief at earlier time points prior to the time of the telephone-administered survey as this would introduce unacceptable recall bias. As such, the maximum pain relief of the C-RFA procedure may have started to dissipate by the time of outcome assessment.
At six-month follow-up, the success rate of 35% (based on strict criteria) in the present study was significantly greater than that reported at six months by Ikeuchi et al. (10%) . This is particularly notable given that participants in the Ikeuchi et al. study had knee OA and pain isolated to the anteromedial aspect of the knee, whereas the majority patients in the present study had bi-or tri-compartmental OA with more diffuse knee pain. To speculate, these superior outcomes may be related to the use of cooled rather than conventional RFA technology. In C-RFA, a constant flow of ambient temperature water is circulated through an internal channel within the electrode via a peristaltic pump, thereby creating a heat sink, preventing the rapid tissue desiccation, charring, and increased tissue impedance around the electrode that can occur with conventional RF lesioning. The 18-gauge cooled RF electrode will create large, spherical 10 mm Â 10 mm lesions, compared with the smaller elliptical lesions produced with conventional 20-gauge or 22-gauge RF electrodes [20, 35] , and the actual tissue temperature reached with cooled RF is 80 C, similar to conventional thermal RF [20] . These larger lesions with cooled RF confer a considerable therapeutic advantage as the probability of successful denervation of targeted sensory afferents is increased. This is especially important when there is patient-topatient neuroanatomic variability. With cooled RFA, the electrode can be positioned at any angle to make contact with the target neural structure, as compared with conventional RF, which necessitates fastidious electrode placement parallel to the targeted sensory afferents [27] . We used the anatomic landmarks based on recent cadaveric dissections of the human knee performed by Franco et al. [12] and placed introducers and electrodes with fluoroscopic guidance. To date, there are no in vivo studies that compare the clinical effectiveness of cooled vs conventional RF ablation of the genicular nerves, but this deserves investigation.
This study was limited by its retrospective and survey design. Ideally, a validated physical disability outcome measure, such as the Western Ontario and McMaster Universities Arthritis Index or Knee Injury and Osteoarthritis Outcome Score, would be used in a prospective study. Factors shown to influence patient pain outcomes after total knee replacement surgery were not assessed. The number of chronic pain sites, catastrophizing, anxiety, depression, and poor levels of preoperative function all predicted poorer outcomes in a large meta-analysis of TKR outcomes in nearly 30,000 patients [4] . As many patients may seek genicular nerve C-RFA as an alternative to TKR, future clinical trials should include these risk factors in patient assessment.
Conclusions
The present data suggest a clinically important improvement in pain that is durable beyond six months in half of patients who undergo C-RFA for chronic pain due to knee osteoarthritis. More than one-third of patients experience clinical success based on a robust combination of patient-reported outcome measures. Nearly 20% of patients experience complete relief of pain. A selection protocol including 80% relief from diagnostic genicular nerve block and a duration of pain at presentation of less than five years are associated with treatment success, yet further investigation of the diagnostic accuracy of this model and other patient selection factors is needed. 3. How would you rate your overall improvement since the radiofrequency ablation procedure to treat your knee pain?: 1 very much improved, 2 improved, 3 slightly improved, 4 no change, 5 slightly worse, 6 worse, 7 very much worse.
4. Since your radiofrequency ablation procedure to treat your knee pain, did you have this knee replaced or other surgery on the knee? 5. Have you experienced any complications or side effects of the radiofrequency ablation procedure to treat your knee pain?
